Literature DB >> 17115032

Tyrosine phosphorylation controls PCNA function through protein stability.

Shao-Chun Wang1, Yusuke Nakajima, Yung-Luen Yu, Weiya Xia, Chun-Te Chen, Cheng-Chieh Yang, Eric W McIntush, Long-Yuan Li, David H Hawke, Ryuji Kobayashi, Mien-Chie Hung.   

Abstract

The proliferating cell nuclear antigen (PCNA) is an essential protein for DNA replication and damage repair. How its function is controlled remains an important question. Here, we show that the chromatin-bound PCNA protein is phosphorylated on Tyr 211, which is required for maintaining its function on chromatin and is dependent on the tyrosine kinase activity of EGF receptor (EGFR) in the nucleus. Phosphorylation on Tyr 211 by EGFR stabilizes chromatin-bound PCNA protein and associated functions. Consistently, increased PCNA Tyr 211 phosphorylation coincides with pronounced cell proliferation, and is better correlated with poor survival of breast cancer patients, as well as nuclear EGFR in tumours, than is the total PCNA level. These results identify a novel nuclear mechanism linking tyrosine kinase receptor function with the regulation of the PCNA sliding clamp.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17115032     DOI: 10.1038/ncb1501

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  154 in total

1.  S-adenosyl methionine regulates ubiquitin-conjugating enzyme 9 protein expression and sumoylation in murine liver and human cancers.

Authors:  Maria Lauda Tomasi; Ivan Tomasi; Komal Ramani; Rosa Maria Pascale; Jun Xu; Pasquale Giordano; José M Mato; Shelly C Lu
Journal:  Hepatology       Date:  2012-07-12       Impact factor: 17.425

Review 2.  Understanding resistance to EGFR inhibitors-impact on future treatment strategies.

Authors:  Deric L Wheeler; Emily F Dunn; Paul M Harari
Journal:  Nat Rev Clin Oncol       Date:  2010-06-15       Impact factor: 66.675

Review 3.  Regulation of DNA replication proteins in parasitic protozoans: possible role of CDK-like kinases.

Authors:  Abhijit S Deshmukh; Meetu Agarwal; Suman Kumar Dhar
Journal:  Curr Genet       Date:  2016-01-16       Impact factor: 3.886

4.  H2O2 induces nuclear transport of the receptor tyrosine kinase c-MET in breast cancer cells via a membrane-bound retrograde trafficking mechanism.

Authors:  Mei-Kuang Chen; Yi Du; Linlin Sun; Jennifer L Hsu; Yu-Han Wang; Yuan Gao; Jiaxing Huang; Mien-Chie Hung
Journal:  J Biol Chem       Date:  2019-04-08       Impact factor: 5.157

5.  Crosstalk between nuclear MET and SOX9/β-catenin correlates with castration-resistant prostate cancer.

Authors:  Yingqiu Xie; Wenfu Lu; Shenji Liu; Qing Yang; Brett S Carver; Estelle Li; Yuzhuo Wang; Ladan Fazli; Martin Gleave; Zhenbang Chen
Journal:  Mol Endocrinol       Date:  2014-08-06

6.  A Peptide mimicking a region in proliferating cell nuclear antigen specific to key protein interactions is cytotoxic to breast cancer.

Authors:  Shanna J Smith; Long Gu; Elizabeth A Phipps; Lacey E Dobrolecki; Karla S Mabrey; Pattie Gulley; Kelsey L Dillehay; Zhongyun Dong; Gregg B Fields; Yun-Ru Chen; David Ann; Robert J Hickey; Linda H Malkas
Journal:  Mol Pharmacol       Date:  2014-12-05       Impact factor: 4.436

7.  PML represses lung cancer metastasis by suppressing the nuclear EGFR-mediated transcriptional activation of MMP2.

Authors:  Hong-Yi Kuo; Yen-Sung Huang; Chin-Hsiu Tseng; Yi-Chen Chen; Yu-Wei Chang; Hsiu-Ming Shih; Cheng-Wen Wu
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 8.  Trafficking of receptor tyrosine kinases to the nucleus.

Authors:  Graham Carpenter; Hong-Jun Liao
Journal:  Exp Cell Res       Date:  2008-10-11       Impact factor: 3.905

9.  Nuclear EGFR is required for cisplatin resistance and DNA repair.

Authors:  Sheng-Chieh Hsu; Stephanie A Miller; Yan Wang; Mien-Chie Hung
Journal:  Am J Transl Res       Date:  2009-03-08       Impact factor: 4.060

Review 10.  Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function.

Authors:  Klaus Dittmann; Claus Mayer; H Peter Rodemann
Journal:  Strahlenther Onkol       Date:  2009-12-28       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.